Evidence map›Paper›PMID 35693220›Full record

ArticlePrecision clinical medicine2021

CRISPR/Cas9 mediated somatic gene therapy for insertional mutations: the

Xin Fu, Jie Zhu, Yaou Duan, Paul Lu, Kang Zhang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Precision clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. CRISPR-guided nanotherapy for rare central sensitization syndromes.Annals of medicine and surgery (2012) · 2025
    Article
  2. Understanding the Molecular Basis of Miller-Dieker Syndrome.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 3 countries.

Xin FuSpine Center, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Jie ZhuGuangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
Yaou DuanDepartment of Nanoengineering, Chemical Engineering Program, and Moores Cancer Center, University of California at San Diego, La Jolla, CA 92093, USA.
Paul LuVA-San Diego Healthcare System, San Diego, CA 92161, USA.
Kang ZhangCenter for Biomedicine and Innovations, Faculty of Medicine, Macau University of Science and Technology, Macao, China.
Guangzhou Medical University · CNMacau University of Science and Technology · MOMoores Cancer CenterShanghai Jiao Tong University · CNVA San Diego Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Somatic gene therapy remains technically challenging, especially in the central nervous system (CNS). Efficiency of gene delivery, efficacy in recipient cells, and proportion of cells required for overall benefit are the key points needed to be considered in any therapeutic approach. Recent efforts have demonstrated the efficacy of RNA-guided nucleases such as CRISPR/Cas9 in correcting point mutations or removing dominant mutations. Here we used viral delivered Cas9 plasmid and two guide RNAs to remove a recessive insertional mutation,

Indexed as

CRISPR/Cas9neurodegenerative diseasePitpnasomatic gene editingvibrator mouse model

Identifiers

PMID35693220
PMCPMC8982555
OpenAlexW3194259384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.